Skip to main content
Midas Edge

AbCellera Biologics Inc

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

ABCL$12.46-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Shares · AdditionalPaid-in Capital · Accumulated Earnings · AccumulatedOtherComprehensiveLoss · TotalShareholders'Equity
Shares · Amount
Balances as of December 31, 2023290,824,970$753,199$121,052$279,787$(1,720)$1,152,318
Shares issued and restricted stock units ("RSUs") vested under stock option plan2,796,34211,363(10,471)--892
Stock-based compensation expense--17,409--17,409
Foreign currency translation adjustment----(96)(96)
Net loss---(40,610)-(40,610)
Balances as of March 31, 2024293,621,312$764,562$127,990$239,177$(1,816)$1,129,913
Common Shares · AdditionalPaid-in Capital · Accumulated Earnings · AccumulatedOtherComprehensiveLoss · TotalShareholders'Equity
Shares · Amount
Balances as of December 31, 2022286,851,595$734,365$74,118$426,185$(1,391)$1,233,277
Shares issued and restricted stock units ("RSUs") vested under stock option plan1,574,9198,451(7,962)--489
Share-based compensation expense--15,474--15,474
Foreign currency translation adjustment----(630)(630)
Net loss---(40,110)-(40,110)
Balances as of March 31, 2023288,426,514$742,816$81,630$386,075$(2,021)$1,208,500
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.